QAMZOVA
Clinical safety rating
cautionComprehensive clinical and safety monograph for QAMZOVA (QAMZOVA).
Comprehensive clinical and safety monograph for QAMZOVA (QAMZOVA).
Treatment of moderate to severe plaque psoriasis in adultsTreatment of active psoriatic arthritis in adults
QAMZOVA is a monoclonal antibody targeting the interleukin-17 receptor A (IL-17RA), blocking the interaction with IL-17 cytokines and inhibiting downstream inflammatory signaling pathways involved in psoriatic disease.
| Metabolism | QAMZOVA is a monoclonal antibody degraded into small peptides and amino acids via catabolic pathways; not metabolized by cytochrome P450 enzymes. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 70-80% of elimination; biliary/fecal elimination accounts for 15-20%. |
| Half-life | Terminal elimination half-life is 12-15 hours in healthy adults; may be prolonged in renal impairment (up to 30-40 hours in severe impairment). |
| Protein binding | 92-97% bound primarily to serum albumin. |
| Volume of Distribution | 0.8-1.2 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: 60-70% (due to first-pass metabolism). |
| Onset of Action | Oral: 1-2 hours; Intravenous: within 15-30 minutes. |
| Duration of Action | Oral: 12-24 hours; Intravenous: 6-12 hours based on dosing interval. |
| Molecular Weight | 500 |
25 mg orally once daily, increased to 50 mg once daily after 4 weeks if tolerated. Maximum 100 mg once daily.
| Dosage form | SOLUTION |
| Renal impairment | eGFR 30-89 mL/min: no adjustment; eGFR 15-29 mL/min: reduce dose to 25 mg once daily; eGFR <15 mL/min or dialysis: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 25 mg once daily; Child-Pugh C: use not recommended. |
| Pediatric use | Weight ≥40 kg: same as adult; weight <40 kg: not established (safety and efficacy not studied). |
| Geriatric use | Initiate at 25 mg once daily; titrate slowly; monitor renal function more frequently. |
| 1st trimester | Limited human data; animal studies suggest risk, but potential benefit may warrant use in serious conditions. Avoid unless clearly needed. |
| 2nd trimester | Limited human data; consider risk-benefit. Use only if clearly indicated. |
| 3rd trimester | Limited human data; consider risk-benefit. Use only if clearly indicated. |
Clinical note
Comprehensive clinical and safety monograph for QAMZOVA (QAMZOVA).
| Placental transfer | Based on molecular weight and limited data, likely crosses placenta; extent unknown. |
| Breastfeeding | No human data on excretion in breast milk. Due to potential for serious adverse reactions, a decision should be made whether to discontinue nursing or discontinue the drug. |
| Lactation Rating | L4 (Possibly Hazardous) |
| Teratogenic Risk | QAMZOVA is contraindicated in pregnancy due to known teratogenicity. First trimester exposure is associated with major congenital malformations including neural tube defects, cardiovascular anomalies, and craniofacial defects. Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and renal impairment. Use effective contraception during treatment. |
| Fetal Monitoring | Perform pregnancy test before initiating therapy and monthly during treatment. Monitor fetal development via ultrasound if pregnancy occurs. Assess renal function and amniotic fluid volume in third trimester. Monitor for signs of fetal growth restriction. |
| Fertility Effects | QAMZOVA may impair female fertility based on animal studies showing reduced ovarian reserve and altered estrous cycles. Reversible upon discontinuation. No data on male fertility; advise use of reliable contraception for both male and female patients. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to QAMZOVA or any componentSevere hepatic impairment
| Precautions | Increased risk of infections, including upper respiratory tract infections and candidiasis, Hypersensitivity reactions including anaphylaxis, Risk of inflammatory bowel disease exacerbation |
| Food/Dietary | No known food interactions. Grapefruit and other CYP3A4 inhibitors do not affect QAMZOVA as it is a monoclonal antibody not metabolized by cytochrome P450 enzymes. |
| Clinical Pearls | QAMZOVA is a monoclonal antibody targeting IL-23; monitor for hypersensitivity reactions during infusion. Premedicate with antihistamines and acetaminophen for infusion reactions. Avoid live vaccines during treatment. Screening for latent TB required before initiation. |
| Patient Advice | Inform your healthcare provider if you have any infections or signs of infection such as fever, chills, or cough. · Avoid receiving live vaccines while taking QAMZOVA. · Report any symptoms of allergic reactions, including rash, itching, or difficulty breathing, especially during or after infusion. · Notify your doctor if you are pregnant, planning to become pregnant, or breastfeeding. · Keep all appointments for infusion therapy and lab work as scheduled. |
Loading safety data…